Evidence map›Paper›PMID 24928783›Full record

ArticleCancer research2014

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Jinfei Xu, Yuwaraj Kadariya, Mitchell Cheung, Jianming Pei, Jacqueline Talarchek, Eleonora Sementino, Yinfei Tan, Craig W Menges, Kathy Q Cai, Samuel Litwin and 4 more

Abstract read
In one paragraph

Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Exposure to cosmetic talc and mesothelioma.Journal of occupational medicine and toxicology (London, England) · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jinfei XuCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Yuwaraj KadariyaCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Mitchell CheungCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jianming PeiCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jacqueline TalarchekCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Eleonora SementinoCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Yinfei TanCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Craig W MengesCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Kathy Q CaiDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Samuel LitwinBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Hongzhuang PengGene Expression and Regulation, Wistar Institute, Philadelphia, Pennsylvania.
Jayashree KararGene Expression and Regulation, Wistar Institute, Philadelphia, Pennsylvania.
Frank J RauscherGene Expression and Regulation, Wistar Institute, Philadelphia, Pennsylvania.
Joseph R TestaCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Joseph.Testa@fccc.edu.

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXLR01CA175691 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAUSCHER III, FRANK JOSEPH, TESTA, JOSEPH R. · 2014 to 2018
$2.7M
Functional Analysis of the BAP1 Metastasis Suppressor Gene in Uveal MelanomaR01CA163761 · NCI · WISTAR INSTITUTE · PI RAUSCHER III, FRANK JOSEPH · 2012 to 2016
$1.8M
NCI NIH HHS CA-06927NCI NIH HHS CA175691NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA163761NCI NIH HHS R01 CA175691NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

Malignant mesotheliomas are highly aggressive tumors usually caused by exposure to asbestos. Germline-inactivating mutations of BAP1 predispose to mesothelioma and certain other cancers. However, why mesothelioma is the predominate malignancy in some BAP1 families and not others, and whether exposure to asbestos is required for development of mesothelioma in BAP1 mutation carriers are not known. To address these questions experimentally, we generated a Bap1(+/-) knockout mouse model to assess its susceptibility to mesothelioma upon chronic exposure to asbestos. Bap1(+/-) mice exhibited a significantly higher incidence of asbestos-induced mesothelioma than wild-type (WT) littermates (73% vs. 32%, respectively). Furthermore, mesotheliomas arose at an accelerated rate in Bap1(+/-) mice than in WT animals (median survival, 43 weeks vs. 55 weeks after initial exposure, respectively) and showed increased invasiveness and proliferation. No spontaneous mesotheliomas were seen in unexposed Bap1(+/-) mice followed for up to 87 weeks of age. Mesothelioma cells from Bap1(+/-) mice showed biallelic inactivation of Bap1, consistent with its proposed role as a recessive cancer susceptibility gene. Unlike in WT mice, mesotheliomas from Bap1(+/-) mice did not require homozygous loss of Cdkn2a. However, normal mesothelial cells and mesothelioma cells from Bap1(+/-) mice showed downregulation of Rb through a p16(Ink4a)-independent mechanism, suggesting that predisposition of Bap1(+/-) mice to mesothelioma may be facilitated, in part, by cooperation between Bap1 and Rb. Drawing parallels to human disease, these unbiased genetic findings indicate that BAP1 mutation carriers are predisposed to the tumorigenic effects of asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure.

Indexed as

Germ-Line MutationAnimalsAsbestosDisease Models, AnimalEpigenomicsFemaleGenetic Predisposition to DiseaseGenotypeLung NeoplasmsMesotheliomaMesothelioma, MalignantMiceMice, KnockoutTumor Suppressor ProteinsUbiquitin ThiolesteraseAsbestosBAP1 protein, mouseTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID24928783
PMCPMC4165574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.